Dr. Thomas Dahl
Chief Executive Officer
Dr. Oscar L. Kashala
Chairman of the Board
The Globex Team
Dr. Oscar Kashala is a native of the Democratic Republic of Congo (DRC) and Chairman of the Board of Directors for Global Enterprise Services Corporation (GLOBEX). He is responsible for overseeing all GLOBEX operations. Dr. Kashala’s professional training is as a medical doctor and cancer specialist. He graduated from the Kinshasa University Medical School in 1980 with honors, and trained in internal medicine and pathology at the University of Kinshasa, then at the University of Lausanne and University of Geneva Medical Schools. Dr. Kashala has worked with governments in the Americas, Africa, Europe, and Asia and therefore has great visibility into the functioning of diverse bureaucracies and implementation of policy at the federal, provincial, and local levels. Additionally, Dr. Kashala’s experiences in the private sector transcends industry and has provided him with an appreciation for the complicated interaction of government and private industry.
Dr. Thomas Dahl is an accomplished executive with a history of management in companies ranging from small start-ups to those with a global footprint. Having held a number of senior management positions across industries, Dr. Dahl provides strength in business strategy and operations, technical analysis of products and technologies, and product development strategy, as well as interfacing with the financial community, analysts and negotiating corporate partnerships. Dr. Dahl also serves and has served in a number of consulting and advisory capacities for companies and institutes in the biotech, pharmaceutical and healthcare spaces, as well as on the Boards of both for-profit and non-profit entities. He has founded and participated in a number of Advisory Boards, both Scientific and Medical, and overseen corporate governance as a Director for multiple companies. He currently serves on the Board of Directors for the non-profit GeneSys Research Institute. Dr. Dahl received his B.A. from Texas Christian University, Fort Worth, Texas and his Ph.D. from The Johns Hopkins University, Baltimore, Maryland.
Dr. Thomas Wong
Chief Strategy Officer
Mr. Kashala maintains an array of international contacts that enables GLOBEX to have a reliable domestic presence and real-time information regarding developments in areas of client interest. Mr. Kashala has experience advising on international political campaigns where his principle duties have development of campaign strategies, stakeholder outreach, fundraising, and communications. Mr. Kashala also has significant experience advising academic institutions and corporations on their educational global engagement strategies Mr. Kashala has served in the American legal industry where he focused primarily on Large Cap transactional law, mergers & acquisitions, and corporate due diligence. Mr. Kashala possesses an undergraduate degree from Tufts University and an MBA from Boston University. He also sits on the Advisory Board of the Trustees of Donations for Education in Liberia, a University of Liberia affiliated board, and is an editorial contributor to the Fair Observer a, Washington D.C. based journal.
Gaetan L. Kashala
Jason Walsh, MBA
Chief Financial Officer
Mr. Walsh, is a senior finance and operations executive with over twenty years of biotechnology management experience. He leads Globex's finance and corporate development activities. Previously, Jason was a founder and Chief Business Officer of the cancer therapeutic company, Provenance Biopharmaceuticals Corp. At Provenance, he led all finance, business operations, and corporate development activities. He raised several rounds of financing and helped advance the company's lead molecule into the clinic. Prior to starting Provenance, Jason was Head of Finance and Business Operations for Lexigen Pharmaceuticals Corp. There, he helped lead Lexigen from its start-up phase through various stages of funding and multiple corporate pharmaceutical company partnerships and, ultimately, to the successful sale to the global pharmaceutical company, Merck KGaA. Prior to his executive position at Lexigen, Jason founded and led several entrepreneurial ventures in a wide range of industries. He is a founder, Treasurer and member of the Board of Directors of The Bioscience Network, a non-profit educational and professional development organization for the life science industry. He has his Masters in Business Administration from Babson College.
Dr. Wong is the Chief Strategy Officer (CSO) for Globex. Dr. Wong has over 20+ years of pharmaceutical product development, program development and clinical trials management experience. He has served in a number of senior positions with both large pharmaceutical companies like Searle and Glaxo and smaller biotech companies like Lexigen and EMD. In addition, Dr. Wong has been in several start-up clinical research companies (and programs) that serve the pharmaceutical and biotech industry. He was also responsible for content development of clinical trial management software that was acquired by Laxor Inc. a Personal Health Record company. Subsequently, Dr. Wong assumed the role of COO for Laxor and served on the company board. For the past decade, he has been interested in the convergence of the pharmaceutical and health care arena. He is co-founder of Xanitaz Health Care Solutions, a health solutions company that is focused on population care management strategies for diabetes in China.
Dr. Wong has served three 3-year terms on the University of North Carolina Gillings School of Global Public Health Foundation Board; he continues to serves the Board as an emeritus member. He has recently joined RTP Capital Group, an angel investment group in North Carolina. Dr. Wong received his BA degree from University of California-Berkeley and his MPH in Health Administration and PhD in Biochemistry from the University of North Carolina-Chapel Hill.